The value of MRI in the detection of axillary lymph node metastases in breast cancer: a systematic review

Staging of the axillary lymph nodes is an essential step to determine the appropriate treatment for breast cancer. Sentinel lymph node biopsy (SLNB) is currently the first step in staging and the gold standard. However, if the sentinel node is positive, a full dissection of the axillary lymph nodes should be performed (axillary lymph node dissection or ALND). This technique used to be the gold standard but had considerable sequelae which diminished quality of life. SLNB still has sequelae but the incidence is much lower. The goal of this systematic review is to assess whether MRI can replace or assist the current gold standard for axillary lymph node staging in breast cancer. With the use of these non-invasive techniques, the risk of morbidity could be reduced even more. A comprehensive search and an additional brief search in several databases has been performed using PRISMA. Studies were selected based on titles and abstracts and were included or excluded using predetermined criteria. The studies were assessed for validity and applicability using the QUADAS2 tool by two readers. Data of three studies using diffusion-weighted imaging (DWI) were pooled and statistical analysis was performed. A total of seven studies were included for review. Three studies used DWI, others used T2-weighted imaging, contrast-enhanced imaging, T1-weighted imaging or an MRI scoring system. Due to the heterogeneously divided MRI modalities, a small meta-analysis of DWI was performed. Other studies were evaluated qualitatively. DWI reached a sensitivity of 87.67% (95% CI 77.88-94.20) and a specificity of 59.31% (95% CI 50.85-67.38), a positive predictive value (PPV) of 52.03% (95 CI 42.84-61.12), and a negative predictive value (NPV) of 90.53% (95% CI 82.78-95.58). MRI can aid in the detection of axillary lymph node metastasis, but it cannot replace the current gold standard (SLNB/ALND).

Sentinel node; Axillary; Staging; MRI; Breast cancer

[1] National Collaborating Centre for Cancer, National Institute for Health and Clinical Excellence: “Guidance. Early and Locally Advanced Breast Cancer: Diagnosis and Treatment”. Cardiff (UK): National Collaborating Centre for Cancer (UK) National Collaborating Centre for Cancer, 2009.

[2] Wildiers H., Stordeur S., Vlayen J., Scholten R., Van De Wetering F., Bourgain C., et al.: “Breast cancer in women: Diagnosis, Treatment and Follow-Up”. Belgian Health Care Knowledge Centrum, 2013, 143, 90.

[3] Verbelen H., Gebruers N., Eeckhout F.M., Verlinden K., Tjalma W.: “Shoulder and arm morbidity in sentinel node-negative breast cancer patients: a systematic review”. Breast Cancer Res Treat., 2014, 144, 21.

[4] Purushotham A.D., Upponi S., Klevesath M.B., Bobrow L., Millar K., Myles J.P., et al.: “Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial”. J. Clin. Oncol., 2005, 23, 4312.

[5] Hwang S.O., Lee S.W., Kim H.J., Kim W.W., Park H.Y., Jung J.H.: “The Comparative Study of Ultrasonography, Contrast-Enhanced MRI, and (18)F-FDG PET/CT for Detecting Axillary Lymph Node Metastasis in T1 Breast Cancer”. J. Breast Cancer, 2013, 16, 315.

[6] Lu Q., Hua J., Kassir M.M., Delproposto Z., Dai Y., Sun J., et al.: Imaging lymphatic system in breast cancer patients with magnetic resonance lymphangiography”. PLoS One, 2013, 8, e69701.

[7] Kamitani T., Hatakenaka M., Yabuuchi H., Matsuo Y., Fujita N., Jinnouchi M., et al.: “Detection of axillary node metastasis using diffusion-weighted MRI in breast cancer”. Clin. Imaging, 2013, 37, 56.

[8] Fornasa F., Nesoti M.V., Bovo C., Bonavina M.G.: “Diffusion-weighted magnetic resonance imaging in the characterization of axillary lymph nodes in patients with breast cancer”. J. Magn. Reson. Imaging, 2012, 36, 858.

[9] Scaranelo A.M., Eiada R., Jacks L.M., Kulkarni S.R., Crystal P.: “Accuracy of Unenhanced MR Imaging in the Detection of Axillary Lymph Node Metastasis: Study of Reproducibility and Reliability”. Radiology, 2012, 262, 425.

[10] Schipper R-J., Paiman M-L., Beets-Tan R.G.H., Nelemans P.J., de Vries B., van de Vijver K., et al.: “Diagnostic Performance of Dedicated Axillary T2- and Diffusion-weighted MR Imaging for Nodal Staging in Breast Cancer”. Radiology, 2015, 275, 345.

[11] He N., Xie C., Wei W., Pan C., Wang W., Lv N., et al.: “A new, pre-operative, MRI-based scoring system for diagnosing malignant axillary lymph nodes in women evaluated for breast cancer”. Eur. J. Radiol., 2012, 81, 2602.

[12] Scaranelo A.M., Eiada R., Jacks L.M., Kulkarni S.R., Crystal P.: “Accuracy of unenhanced MR imaging in the detection of axillary lymph node metastasis: study of reproducibility and reliability”. Radiology, 2012, 262, 425.

[13] Harnan S.E., Cooper K.L., Meng Y., Ward S.E., Fitzgerald P., Papaioannou D., et al.: “Magnetic resonance for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis”. Eur. J. Surg. Oncol., 2011, 37, 928.

[14] Harada T., Tanigawa N., Matsuki M., Nohara T., Narabayashi I.: “Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging”. Eur. J. Radiol., 2007, 63, 401.

[15] Hudgins P.A., Anzai Y., Morris M.R., Lucas M.A.: “Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study”. AJNR Am. J. Neuroradiol., 2002, 23, 649.

[16] Kuijs V.J., Moossdorff M., Schipper R.J., Beets-Tan R.G., Heuts E.M., Keymeulen K.B., et al.: “The role of MRI in axillary lymph node imaging in breast cancer patients: a systematic review”. Insights Imaging, 2015, 6, 203.

[17] Wu L., Cao Y., Liao C., Huang J., Gao F.: “Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: A meta-analysis”. Eur. J. Radiol., 2011, 80, 582.

[18] Cooper K.L., Meng Y., Harnan S., Ward S.E., Fitzgerald P., Papaioannou D., et al.: “Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation”. Health Technol. Assess., 2011, 15, 1.

[19] Nemmar A., Beegam S., Yuvaraju P., Yasin J., Tariq S., Attoub S., et al.: “Ultrasmall superparamagnetic iron oxide nanoparticles acutely promote thrombosis and cardiac oxidative stress and DNA damage in mice”. Part. Fibre Toxicol., 2016, 13, 22.

[20] Ali L.M., Gutierrez M., Cornudella R., Moreno J.A., Pinol R., Gabilondo L., et al.: “Hemostasis disorders caused by polymer coated iron oxide nanoparticles”. J. Biomed. Nanotechnol., 2013, 9, 1272.

[21] Schipper R.J., Smidt M..L, van Roozendaal L.M., Castro C.J., de Vries B., Heuts E.M., et al.: “Noninvasive nodal staging in patients with breast cancer using gadofosveset-enhanced magnetic resonance imaging: a feasibility study”. Invest. Radiol., 2013, 48, 134.

[22] Huang T.W., Kuo K.N., Chen K.H., Chen C., Hou W.H., Lee W.H., et al.: “Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system”. Int. J. Surg., 2016, 34, 73.

[23] Donker M., van Tienhoven G., Straver M.E., Meijnen P., van de Velde C.J., Mansel R.E., et al.: “Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981- 22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial”. Lancet Oncol., 2014, 15, 1303.